argenx commenced a tender offer for Forte Biosciences, a clinical-stage company whose sole meaningful asset is FB102, a proprietary anti-CD122 monoclonal antibody. The offer opened this week. No dollar figure disclosed yet, but Forte's enterprise value sits near $47 million after eighteen months of corridor pricing. argenx typically moves when it sees clear mechanistic differentiation in early immunology.
Forte's FB102 targets CD122, the beta subunit of the interleukin-2 and interleukin-15 receptor. The antibody is in Phase 2 trials for moderate-to-severe atopic dermatitis and remains uncommitted to a lead indication. Forte burned through $18.3 million in the trailing twelve months and held $22 million cash as of the most recent filing. The runway was short. argenx's tender bypasses the usual merger agreement structure, suggesting either competing interest or a desire to avoid drawn-out board negotiations. Forte's stock traded below $1.80 the day before the announcement, well under its $11.40 debut price in 2020.
The acquisition logic is narrow but defensible. argenx built its franchise on neonatal Fc receptor antagonism with efgartigimod, which crossed $600 million in annualized revenue this quarter. The company has been explicit about pursuing complementary mechanisms in autoimmune and inflammatory disease, particularly where antibody depletion or T-cell modulation can serve overlapping patient populations. CD122 blockade suppresses regulatory T-cells and effector memory populations without full lymphodepletion. If FB102 proves synergistic with efgartigimod in skin or systemic autoimmune conditions, argenx gains optionality across its existing commercial infrastructure. If it does not, the writedown is containable.
What allocators should watch: the tender period typically closes within 20 to 25 business days unless extended. argenx will file the offer documents with the SEC within 72 hours of commencement, revealing price per share and any conditions precedent. Watch for competing bids from mid-tier dermatology specialists or Asian pharma with autoimmune pipelines. Forte's Phase 2 readout in atopic dermatitis is expected in the second half of 2025; if argenx closes before data, it signals confidence in earlier interim signals. Also monitor whether argenx retains Forte's Richmond, California site or folds the program into its Belgium or Boston operations.
The tender structure suggests argenx wanted speed over consensus. Forte's board likely had little leverage and shorter runway than the market assumed.